Correlation Between Vitamin D and Symptoms Severity of Autonomic Nervous Mediated Syncope Child and it 's RAAS

Correlation Between Vitamin D and Symptoms Severity of Autonomic Nervous Mediated Syncope（NMS） Child and it 's RAAS

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04844957

Enrollment

100

Registered

2021-04-14

Start date

2020-05-20

Completion date

2022-12-20

Last updated

2022-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D

Keywords

children ; VVS； vitamin D ; symptom score ; RAAS

Brief summary

children ; autonomic nervous mediated syncope； vitamin D ; symptom score ; renin-angiotensin-aldosterone-system

Detailed description

children with autonomic nervous mediated syncope have seriously affects children's physical and mental health and quality of life, and the incidence rate is also increasing year by year. But the current treatment measures are not ideal, Therefore, we need to look for new biological indicators, according to different biological indicators to develop different treatment options, so as to improve the current situation of poor treatment of children with NMS

Interventions

DRUGVitamin D

Clinical Study

DEVICEFull automatic chemiluminescence measuring instrument

Chemiluminescence immunoassay

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

5 Years to 14 Years

Healthy volunteers

Yes

Inclusion criteria

* Children diagnosed with OI; * Compliance with the diagnostic guidelines for Syncope in children (2016 edition) and 2018 syncope in children and adolescents in the cardiovascular group of the Society of Pediatrics, Chinese Medical Association The diagnostic criteria of Oi in the Diagnostic and therapeutic guidelines.

Exclusion criteria

* Taken 3 months prior to admission Vitamin D or hormone drugs; * Heart, brain, nerves, metabolism, blood and other apparatus Syncope or aura of syncope caused by a qualitative disease;

Design outcomes

Primary

Measure	Time frame	Description
Vitamin D levels	3 months after taking the drug	Vitamin D levels after supplementation

Secondary

Measure	Time frame	Description
RAAS levels	3 months after taking the drug	RAAS levels after vitamin D supplementation

Other

Measure	Time frame	Description
OI symptom scores	3 months after taking the drug	OI symptom scores after vitamin D supplementation

Countries

China

Contacts

Primary Contactyujie Kong, M.D

13523396714@163.com18709316966

Backup Contactxiangyu Dong, Professor

dxy0223@163.com13609370003

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026